Aclaris Therapeutics, Inc.(ACRS)Stock Analysis

ACRS Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Aclaris Therapeutics, Inc. (ACRS), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores ACRS at 9.2/100 on a 32-signal composite quality model, placing it at rank #2,818 of 2,879 stocks — the bottom half of the AI-ranked universe. ACRS scores in the top quartile across institutional flow (90.2). Areas of concern include free cash flow (2.8) and profitability (2.9), which score below median versus the broader universe. Shareholder dilution risk is elevated at 2.1/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), Aclaris Therapeutics, Inc. reports quarterly revenue of $2.0M, net income of $-19.8M, free cash flow of $-18.2M. Top institutional holders of ACRS by reported 13-F value include BML Capital Management,, Deep Track Capital,, BlackRock,, based on the most recent SEC filings. ACRS trades on the Nasdaq exchange and files with the SEC under CIK 1557746. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate ACRS daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Aclaris Therapeutics, Inc. directly from SEC EDGAR.